君实生物(SH688180)27日晚发布的2024年年报显示,公司净亏损额继续同比缩窄。君实生物自2023年起连续两年实现营业收入同比提升、净亏损额连续缩窄,且2024年的同比减亏幅度明显扩大。 君实生物的业绩改善主要得益于核心产品特瑞普利单抗。去年,特瑞普利单抗去年在国内实现了15.01亿元销售收入,同比增长66%,约占公司整体营收的77%。公司方面在业绩说明会上表示,多项新适应症获批、医保...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.